Back to Search Start Over

Mortality with Paclitaxel-Coated Devices in Peripheral Artery Disease

Authors :
Nordanstig, Joakim
James, Stefan
Andersson, Manne
Andersson, Mattias
Danielsson, Peter
Gillgren, Peter
Delle, Martin
Engström, Jan
Fransson, Torbjörn
Hamoud, Maher
Hilbertson, Anna
Johansson, Patrik
Karlsson, Lars
Kragsterman, Björn
Lindgren, Hans
Ludwigs, Karin
Mellander, Stefan
Nyman, Niklas
Renlund, Henrik
Sigvant, Birgitta
Skoog, Per
Starck, Joachim
Tegler, Gustaf
Toivola, Asko
Truedson, Maria
Wahlgren, Carl-Magnus
Wallinder, Jonas
Öjersjö, Andreas
Falkenberg, Mårten
Nordanstig, Joakim
James, Stefan
Andersson, Manne
Andersson, Mattias
Danielsson, Peter
Gillgren, Peter
Delle, Martin
Engström, Jan
Fransson, Torbjörn
Hamoud, Maher
Hilbertson, Anna
Johansson, Patrik
Karlsson, Lars
Kragsterman, Björn
Lindgren, Hans
Ludwigs, Karin
Mellander, Stefan
Nyman, Niklas
Renlund, Henrik
Sigvant, Birgitta
Skoog, Per
Starck, Joachim
Tegler, Gustaf
Toivola, Asko
Truedson, Maria
Wahlgren, Carl-Magnus
Wallinder, Jonas
Öjersjö, Andreas
Falkenberg, Mårten
Publication Year :
2020

Abstract

BACKGROUND: The results of a recent meta-analysis aroused concern about an increased risk of death associated with the use of paclitaxel-coated angioplasty balloons and stents in lower-limb endovascular interventions for symptomatic peripheral artery disease. METHODS: We conducted an unplanned interim analysis of data from a multicenter, randomized, open-label, registry-based clinical trial. At the time of the analysis, 2289 patients had been randomly assigned to treatment with drug-coated devices (the drug-coated-device group, 1149 patients) or treatment with uncoated devices (the uncoated-device group, 1140 patients). Randomization was stratified according to disease severity on the basis of whether patients had chronic limb-threatening ischemia (1480 patients) or intermittent claudication (809 patients). The single end point for this interim analysis was all-cause mortality. RESULTS: No patients were lost to follow-up. Paclitaxel was used as the coating agent for all the drug-coated devices. During a mean follow-up of 2.49 years, 574 patients died, including 293 patients (25.5%) in the drug-coated-device group and 281 patients (24.6%) in the uncoated-device group (hazard ratio, 1.06; 95% confidence interval, 0.92 to 1.22). At 1 year, all-cause mortality was 10.2% (117 patients) in the drug-coated-device group and 9.9% (113 patients) in the uncoated-device group. During the entire follow-up period, there was no significant difference in the incidence of death between the treatment groups among patients with chronic limb-threatening ischemia (33.4% [249 patients] in the drug-coated-device group and 33.1% [243 patients] in the uncoated-device group) or among those with intermittent claudication (10.9% [44 patients] and 9.4% [38 patients], respectively). CONCLUSIONS: In this randomized trial in which patients with peripheral artery disease received treatment with paclitaxel-coated or uncoated endovascular devices, the results of an unplanned interim analysis of all-c

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1235309232
Document Type :
Electronic Resource
Full Text :
https://doi.org/10.1056.NEJMoa2005206